Puromycin (CL13900) 2HCl | ≥99%(HPLC) | Selleck | Antineoplastic and Immunosuppressive Antibiotics inhibitor

Puromycin (CL13900) 2HCl Chemical Structure

CAS No. 58-58-2

Selleck's Puromycin (CL13900) 2HCl has been cited by 86 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Related Compound Libraries

Other Antineoplastic and Immunosuppressive Antibiotics Products

Download Inhibitor Catalog

Biological Activity

Description

Puromycin 2HCl (CL13900) is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.

In vitro

The antibiotic puromycin is produced by the actinoniycete, Streptornyces alboniger, and has been used as a tool for studying protein synthesis in a number of systems. ^[1] Puromycin can be used for the selection of recombinant cells from noncultured cells. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

K562	Mn3GS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MknIO\|IhcA>?	NXy0RlRZT3Kxd4ToJIlvcGmkaYTpc44hd2ZiZH;4c5J2[mmlaX6tdoV{cXO2YX70JIh2dWGwIFu1OlIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OD1{Nj64N{DPxE1w	NU\sTlVZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizNVM{ODdpPkG4N\|E{OzB5PD;hQi=>
HepG2	MkTtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NHq2R\|U4OiCq	NF\i[3pIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJ\XCJMjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOjNizszNMi=>	NFXFV3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOxN\|MxPyd-MUizNVM{ODd:L3G+
K562	NUPMbWlIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MYm3NkBp	NGCzbJZIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBMPTZ{IHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4zOiEQvF2u	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDNzM{OwO{c,OTh\|MUOzNFc9N2F-
HepG2	MoPtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NGTMWmM4OiCq	NV3GU2t[T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjJzIN88UU4>	NVrPR45sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1NVI6QDRpPkG4OVEzQTh2PD;hQi=>
Huh7	NHL4W5dEgXSxdH;4bYNqfHliYYPzZZk>		NG[zO2dPV1[DUmTJV\|ohS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hcGWyYYTvZ4VtdHWuYYKgZ4Fz[2mwb33hJINmdGxibHnu[UApUHWqNzmsJGNEPTB;Nj62N{DPxE1w	MojmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3N{m3PFMoRjF6NUe5O\|g{RC:jPh?=
HEK239	NHH1bZJEgXSxdH;4bYNqfHliYYPzZZk>	M1LheVczKGh?	NVv2OpR1S3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlM6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDBcIFu[XJiYnz1[UBie3OjeTygTWM2OD1yLkSyJO69VS5?	M3\tblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUW4NFYxLz5{MEW1PFA3ODxxYU6=
J774A1	M{f2XGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MniwR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgTlc4PEFzIHPlcIx{KGK7IITyfZBidiCkbIXlJIV5[2y3c3nvckBie3OjeTygTWM2OD1zMDFOwG0v	NYnmZlJHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5N\|Q3OzZpPkKyPVM1PjN4PD;hQi=>
KB3-1	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFz2dWc4OiCqcoO=	Mmn6S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gT2I{NTFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOjFizszNMi=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDNzM{OwO{c,OTh\|MUOzNFc9N2F-
HepG2/Dox	M13hV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NFK5T2Q4OiCqcoO=	MVfHdo94fGhiaX7obYJqfGmxbjDv[kBufWy2aXTyeYchemW\|aYP0ZY51KGi3bXHuJGhmeEd{L1TvfEBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMkCuNkDPxE1w	MmnEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3MUK5PFQoRjF6NUGyPVg1RC:jPh?=
HEK293	MWXDfZRwfG:6aXPpeJkh[XO\|YYm=	MonBO\|IhcHK\|	MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KHKnc3H6eZJqdi2kYYPl[EBxdGG2ZTDy[YFl\XJiYX7hcJl{cXNuIFnDOVAhRSByLkO2NUDPxE1w	NHjWbmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NVU{Pyd-Mk[2OVE2Ozd:L3G+
HEK293	MofNR5l1d3SxeHnjbZR6KGG\|c3H5	MoK4O\|IhcHK\|	NWT1fZJQS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjN3MEWg{txONg>?	M4H2VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO\|Y{Lz5{N{C2NFc3OzxxYU6=
A549	MVPDfZRwfG:6aXPpeJkh[XO\|YYm=		M2\2WmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMtKEmFNUCgQUAxNjZizszNMi=>	NHzuT2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C4PVIyPCd-MkewPFkzOTR:L3G+
PC3	MULDfZRwfG:6aXPpeJkh[XO\|YYm=		MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOsJGlEPTBiPTCwMlch\|ryPLh?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB6OUKxOEc,OjdyOEmyNVQ9N2F-
HEK293	MnrvR5l1d3SxeHnjbZR6KGG\|c3H5		NUW4dXVbS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hOC5yMECzOUDPxE1w	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzJzMkC3NEc,Ojd{MUKwO\|A9N2F-
HEK293	Mo\qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVPwSWNkPzJiaILz	MnXnS5Jwf3SqIHnubIljcXSrb36gc4YhUEWNMkmzJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCScnXzeI9DdHWnIIP0ZYlvcW6pIHLhd4VlKG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwM{[g{txONg>?	M{jWN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MECxNFY4Lz5{OECwNVA3PzxxYU6=
HEK293	Mk[wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3PDRWdzd3e2aDDpcohq[mm2aX;uJI9nKEiHS{K5N{Bk\WyuczygTWM2OCB;IECuN\|k6KM7:TT6=	NHfZSVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESwNFI{OSd-Mki0NFAzOzF:L3G+
SU-DHL10	MmXMR5l1d3SxeHnjbZR6KGG\|c3H5	MWO3NkBpenN?	M{\hXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNWNUSKTEGwJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2cnWtS4xwKGy3bXnu[ZNk\W62IHHzd4F6NCCFQ{WwJF0hOC5zMTFOwG0v	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV{M{GwN{c,Ojh3MkOxNFM9N2F-
MIAPaCa2	MmrtR5l1d3SxeHnjbZR6KGG\|c3H5	NHflOXM4OiCqcoO=	NF;ZNYNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOUUGSYVPhNkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdILlMWdtdyCudX3pcoV{[2WwdDDhd5NigSxiQ1O1NEA:KDBwMjFOwG0v	NFnad\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEWyN\|ExOyd-Mki1NlMyODN:L3G+
MDA-MB-231	NUj0SmRMS3m2b4TvfIlkcXS7IHHzd4F6	MUW3NkBpenN?	NXHTNpp1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW\|Y3XueEBie3OjeTygR2M2OCB;IECuOFgh\|ryPLh?=	M4HnW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUKzNVA{Lz5{OEWyN\|ExOzxxYU6=
HEK293	MlW0R5l1d3SxeHnjbZR6KGG\|c3H5	M3nqdFczKGi{cx?=	NHO0dWREgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSByLkS2JO69VS5?	M2riTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{e0OFI4Lz5{OEe3OFQzPzxxYU6=
HL60	MXTBcpRqeGG{YYPpeIlkKGG\|c3H5	NELReoY4OiCqcoO=	NWnSN\|I6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGVEPTBiPTCwMlA2PSEQvF2u	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDhyM{C0O{c,Ojh6MEOwOFc9N2F-
MOLT4	NVrIO3R7SW62aYDhdoF{cXSrYzDhd5NigQ>?	NEHHb3Q4OiCqcoO=	Mn\WRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPT1zUOEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDFR\|UxKD1iMD6xO{DPxE1w	M{\OelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OECzNFQ4Lz5{OEiwN\|A1PzxxYU6=
Vero	M4LtbGN6fG:2b4jpZ4l1gSCjc4PhfS=>	NYnreIR[PzJiaILz	NI\2d\|FEgXSxdH;4bYNqfHliYXfhbY5{fCCDZoLpZ4FvKGe{ZXXuJI1wdmuneTDW[ZJwKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygR2M2OCB;IEKuPEDPxE1w	NVzSSFJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4NFMxPDdpPkK4PFA{ODR5PD;hQi=>
HEK293	MWDDfZRwfG:6aXPpeJkh[XO\|YYm=	NHzmN2c4OiCqcoO=	NYC3cY5SS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDy[ZNignW{aX6g[JlmKGKjc3XkJIF{e2G7LDDJR\|UxKD1iMD60OUDPxE1w	NHvLR5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKzOlQ6Oid-MkmyN\|Y1QTJ:L3G+
HEK293T	MlzMR5l1d3SxeHnjbZR6KGG\|c3H5	MUW3NkBpenN?	NXXGNGlJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEWNMkmzWEBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyC{ZXHn[Y51KGKjc3XkJIx2dWmwZYPj[Y5k\SCjc4PhfUwhS0N3MDC9JFAvPDJizszNMi=>	M3XSclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[5OVc2Lz5{OUS2PVU4PTxxYU6=
HCT8	NF;0dJlCdnSrcHHyZZNqfGmlIHHzd4F6	MljVOFghcHK\|	MmjtRY51cXCjcnHzbZRq[yCjY4Tpeol1gSCjZ3HpcpN1KEO{eYD0c5Nxd3KrZHn1cUBx[XK4dX2gRmdHKGmwZnXjeIVlKGmwIHj1cYFvKEiFVEigZ4VtdHNiaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhTkmWQz;ERXBKKHO2YXnubY5oKGKjc3XkJIZtfW:{ZYPj[Y5k\SCjc4PhfUwhTUN3MDC9JFAvPTVizszNMi=>	NE\Ed2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2PVU4PSd-Mkm0Olk2PzV:L3G+
HCT8	MknERY51cXCjcnHzbZRq[yCjc4PhfS=>	MnXoOFghcHK\|	NXfiXYhRSW62aYDhdoF{cXSrYzDhZ5Rqfmm2eTDh[4FqdnO2IFPyfZB1d3Oyb4Lp[Il2dSCyYYL2eY0hW1COIHnu[oVkfGWmIHnuJIh2dWGwIFjDWFgh[2WubIOgbY5kfWKjdHXkJIZweiB2ODDodpMh[nliRlnUR{9FSVCLIIP0ZYlvcW6pIHLhd4VlKG[udX;y[ZNk\W6lZTDhd5NigSxiRVO1NEA:KDBwNjFOwG0v	MmPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nkm1O\|UoRjJ7NE[5OVc2RC:jPh?=
HepG2	NHfleppEgXSxdH;4bYNqfHliYYPzZZk>	NGPnPVg4OiCqcoO=	M1;n[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJJJm[WenboSgZoF{\WRibIXtbY5me2OnbnPlJIF{e2G7LDDDR\|UxKD1iMD64N{DPxE1w	NV62colMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0Olk2PzVpPkK5OFY6PTd3PD;hQi=>
HCT8	M2nOXWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M4\uPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDhiY3XscJMtKEWFNUCgQUA3NjFizszNMi=>	NFS1WIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2PVU4PSd-Mkm0Olk2PzV:L3G+
HEK293	NEDQdpREgXSxdH;4bYNqfHliYYPzZZk>	NELXTGY4OiCqcoO=	NGfzN5JEgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO\|YYmsJGlEPTBiPTCwMlQ3KM7:TT6=	MorzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{O2NVEoRjJ7NUOzOlEyRC:jPh?=
HEK293	M1jpdmN6fG:2b4jpZ4l1gSCjc4PhfS=>	M2f4XlczKGi{cx?=	NEK4N3pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJTUt{OUOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHKnc3H6eZJqdiCmeXWgZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxKD1iMD60JO69VS5?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl4OUK2Nkc,Ojl7NkmyOlI9N2F-
A549	NFHZR3FEgXSxdH;4bYNqfHliYYPzZZk>	M2DGTVQ5KGi{cx?=	M3rlXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzMEBKSzVyIE2gNE4{KM7:TT6=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODRzOEe2N{c,OzB2MUi3OlM9N2F-
PC3	NUPjU3VES3m2b4TvfIlkcXS7IHHzd4F6	NUe2UI1nPDhiaILz	MlXtR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czygTWM2OCB;IECuN{DPxE1w	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODRzOEe2N{c,OzB2MUi3OlM9N2F-

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	Cyclin D1 / CDK4 ; PARP / Bcl-xL / Bcl-2 / p-Akt / Akt ; p53 / p21 / c-Myc	31022952
Growth inhibition assay	Cell viability	31022952

Protocol (from reference)

References	[1] Darken MA. Pharmacol Rev. 1964, 16, 223-243. [2] Watanabe S, et al. Biol Reprod. 2005, 72(2), 309-315.

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL warmed (183.67 mM)
	Water	100 mg/mL warmed (183.67 mM)
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	544.43
Formula	C₂₂H₂₉N₇O₅.2HCl
CAS No.	58-58-2
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CN(C)C1=NC=NC2=C1N=CN2C3C(C(C(O3)CO)NC(=O)C(CC4=CC=C(C=C4)OC)N)O.Cl.Cl

Download Puromycin (CL13900) 2HCl SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):